FDA inspection risk in 2026 is shifting in ways most quality teams haven't fully reckoned with. Here's what DOGE-driven staffing cuts actually mean for pharmaceutical and life sciences manufacturers — and why internal QMS readiness has never mattered more.

Quality Management in a DOGE Environment: What FDA Staffing Reductions Mean for Inspection Risk in 2026

TLDR

• The Trump administration eliminated roughly 3,500 FDA employees (nearly 20% of the agency's workforce) in April 2025, with additional cuts preceding that wave in February 2025.
• Despite reduced staff, FDA warning letters from CDER jumped 50% in FY 2025, and overall agency warning letters rose 73% in the second half of 2025 compared to the same period in 2024.
• Overseas inspection logistics have been disrupted, with only about one-third of laid-off travel coordination staff reinstated, according to ProPublica reporting.
• FDA launched an AI targeting system called "Elsa" in June 2025, shifting inspections from routine to risk-based, meaning companies with unresolved FDA Form 483 observations or open CAPAs face disproportionate scrutiny.
• The counterintuitive conclusion: when you're inspected less frequently but with greater precision, your internal QMS must be in better shape, not worse.

The DOGE Effect on FDA: What Actually Happened

Beginning in February 2025 and accelerating through April, the Department of Government Efficiency drove a sweeping reduction in federal civilian employment. At the FDA, the Department of Health and Human Services terminated approximately 3,500 employees on April 1, 2025, representing close to 20% of the agency's total workforce. This followed an earlier reduction in February that eliminated hundreds of additional positions.

HHS Secretary Robert F. Kennedy Jr. framed the cuts as organizational realignment: "We aren't just reducing bureaucratic sprawl. We are realigning the organization with its core mission and our new priorities in reversing the chronic disease epidemic." FDA leadership simultaneously assured regulated industries that inspector headcount would not be affected.

The reality on the ground has been more complicated. ProPublica reported that approximately 70 support staff who coordinated travel logistics, translators, visas, and budgets for overseas drug inspections were let go. Only about one-third have been reinstated. One veteran FDA drug inspector described the situation directly: "It's difficult to get inspections done. The pace has slowed down. You can't inspect as many sites."

Former FDA Commissioner Margaret Hamburg offered a pointed analogy: "You can't just expect the inspector to take care of all the complexities of organizing their trips overseas. Even though it might be said we've kept the inspectors, that doesn't mean that they've kept the infrastructure that actually supports safe and meaningful inspections."

Janet Woodcock, who ran the FDA's Center for Drug Evaluation and Research for more than two decades before retiring in 2024, put it in starker terms: "It's like saying, 'Oh we didn't fire any of the doctors or nurses at the hospital, but we fired all the lab techs, all the orderlies, all the phlebotomists — oh, but the doctors and nurses are still left so it's fine.'"

Beyond support staff, Citeline's Pink Sheet reported that the FDA lost one-fifth of its review staff over the course of 2025, a departure rate that outpaced any hiring efforts.

The Inspector Capacity Problem Is Not New — DOGE Made It Worse

The FDA's Office of Regulatory Affairs had a retention and capacity problem long before DOGE arrived. According to the Government Accountability Office, between 2022 and 2024, the FDA hired 105 inspectors but lost approximately the same number to attrition, leaving the domestic and international inspection pool at roughly 230 investigators. About one-third of those lacked the experience necessary to conduct independent foreign inspections.

Current FDA inspectors told the GAO the agency needs an additional 100 to 200 experienced investigators to adequately cover the global manufacturing landscape it oversees, which includes drug-making facilities across more than 90 countries.

DOGE did not create this gap. But the loss of administrative and logistics infrastructure in early 2025 further constrained a system already operating below what experienced inspectors say is the necessary threshold.

So Did FDA Enforcement Actually Decline?

This is where the situation becomes counterintuitive, and where many quality leaders have drawn the wrong conclusions.

Enforcement activity did not fall. It accelerated.

According to analysis by Reed Smith published in December 2025, the FDA issued 327 warning letters between July 1 and December 3, 2025 — a 73% increase compared to the same period in 2024. CDER warning letters alone jumped 50% in fiscal year 2025, confirmed by Jill Furman, director of CDER's Office of Compliance, at the 2025 Enforcement, Litigation, and Compliance Conference.

The untitled letter surge was even more dramatic. In fiscal year 2025, the FDA issued 58 untitled letters, up from 5 in FY 2024 and 4 in FY 2023. These letters formally address violations including adulteration, misbranding, and quality system failures.

By product category, drug warning letters rose from 167 in FY 2024 to 249 in FY 2025. Device warning letters increased from 42 to 45. Biologics rose from 15 to 26. The FDA also conducted 694 more inspections agency-wide in FY 2025 than it did in FY 2024.

The enforcement machine accelerated while the logistics infrastructure shrank. That combination reveals something important about how FDA inspections now operate.

Risk-Based Targeting: How "Elsa" Changes the Inspection Equation

In June 2025, the FDA launched an internal AI system called "Elsa" — a predictive analytics tool that analyzes adverse event reports, historical FDA Form 483 observations, anomalies in compliance data, and prior inspection outcomes to prioritize which facilities receive inspections.

Elsa represents a formal shift from calendar-based inspection scheduling toward risk-driven targeting. Facilities that have open observations, unresolved CAPA actions, adverse event anomalies, or prior inspection issues are more likely to be flagged for follow-up, regardless of when their last inspection occurred.

For companies with clean, well-documented QMS records, this may mean longer intervals between routine inspections. For companies with unresolved quality system issues, it may mean the opposite — more frequent contact from an agency that now uses data to find them.

The FDA also expanded its use of unannounced inspections at overseas manufacturing facilities in May 2025, particularly targeting China- and India-based sites that supply a substantial portion of active pharmaceutical ingredients to the US market. The agency made explicit that it has authority to issue import alerts and pursue criminal penalties against companies that delay, deny, or limit inspections.

The Real Inspection Risk in 2026 for Regulated Companies

The staffing reductions create a specific pattern: fewer inspections on a routine basis, but higher precision when inspections do occur. Inspectors under resource pressure do not conduct wide, exploratory reviews. They go in with data, they go in targeted, and they prioritize the most significant observations.

That means the consequences of internal QMS drift are not offset by reduced inspection frequency. If anything, the risk profile has shifted in ways that penalize companies more severely when they are inspected.

Consider the audit trail gap problem. Before Elsa, an unresolved CAPA might sit in a queue without triggering further agency attention until a routine inspection occurred. Under a risk-based model, the same open CAPA — if associated with an adverse event report or a prior 483 observation — may draw proactive attention regardless of inspection scheduling. The data-to-enforcement pathway has shortened.

Similarly, pre-approval inspection timelines for drug applications are under strain. With fewer logistics staff supporting complex overseas inspections, PAI scheduling delays are a real operational risk for companies awaiting approval. Companies with demonstrably clean quality systems and well-organized facilities may have a meaningful advantage in getting through PAI efficiently, because inspectors can move through the review faster when the documentation is in order and CAPA records are closed.

The counterintuitive conclusion holds: shrinking FDA capacity does not reduce compliance risk. It concentrates it.

What the 2025 Audit Data Reveals About Ground-Level Risk

A 2025 GxP audit analysis by The FDA Group examined 33 GMP, GCP, GDP, and ISO audits conducted across five countries between July and November 2025. While no critical findings emerged, the same preventable gaps appeared repeatedly across company sizes, geographies, and maturity levels:

• Documentation and change management gaps made solid processes indefensible
• CAPAs were slow, overdue, or failed to trigger when they should have
• Qualification work for HVAC, equipment, and utilities lagged during expansions
• Supplier oversight and change notification timelines did not match quality agreements
• Annual Product Reviews and management reviews were late or incomplete
• Lab data integrity risks stemmed from procedural shortcuts

These are exactly the findings that get surfaced under risk-based inspection targeting. They are also exactly the gaps that a well-implemented QMS should prevent. The companies that manage these processes with rigor inside their own walls are not waiting for an inspector to tell them something is wrong.

Building an Inspection-Ready QMS Regardless of Inspection Frequency

The shift in FDA's inspection posture does not change what regulated companies need to do. It does change the cost of not doing it.

An inspection-ready QMS is one that operates consistently with or without an inspector present. The quality of your CAPA management, your audit documentation, your change control records, and your risk register is not something you optimize for visits — it is something you maintain as a standing operational reality.

A cloud-based QMS built on a platform like Cloudtheapp gives quality teams several specific advantages in this environment:

Centralized CAPA visibility: Every open corrective action has an assigned owner, a due date, and an escalation path. Nothing ages in a spreadsheet or disappears when someone leaves the company. Under Elsa's risk-based model, companies with closed, documented CAPA records are less likely to be flagged.

Automated audit trails: Every system action — record creation, modification, approval, rejection — is captured in an immutable log. When inspectors request documentation, the audit trail is complete and retrievable in seconds, not days.

Configurable compliance frameworks: Cloudtheapp supports 21 CFR Part 820 (QMSR), 21 CFR Part 11, ISO 13485, ISO 9001, and ISO 22001 natively. As FDA's inspection criteria shift with regulatory updates, the platform adapts without requiring the company to rebuild its quality architecture from scratch.

Internal audit execution: Companies using Cloudtheapp's built-in audits module conduct structured internal audits that mirror FDA's own inspection frameworks. The findings become evidence of a self-correcting quality system — exactly the kind of documentation that supports favorable inspection outcomes.

Risk register integration: Risk-based thinking is no longer optional under QMSR and ISO 13485. With Elsa now using adverse event and risk data to target inspections, maintaining a current, defensible risk register is a direct inspection risk management tool, not an administrative exercise.

What Quality Leaders Should Do Now

The DOGE-driven changes to FDA staffing do not justify reducing internal compliance investment. They justify the opposite. Here is where to focus in the second half of 2026:

Close open CAPAs before they become data signals: Elsa monitors unresolved observations and corrective action gaps. Every open CAPA is a data point in a system that is now actively used to prioritize inspections.

Conduct a current-state internal audit: Do not wait for an external trigger. Run a structured internal audit using FDA's own inspection focus areas: CAPA systems, change control, data integrity, supplier qualification, and process validation. Map findings to your risk register and close them with documented evidence.

Prepare your audit trail documentation for rapid retrieval: Inspectors under resource pressure move faster. If your documentation retrieval is slow or disorganized, you lose time and create impressions that work against you. Electronic QMS systems with centralized document repositories and automated audit trails dramatically reduce this exposure.

Review your PAI timeline if you have pending applications: With overseas inspection logistics still strained, pre-approval inspections may take longer to schedule. Facilities that are demonstrably ready — clean records, closed observations, organized documentation — stand to move through the process more efficiently.

Ensure your escalation paths are current: Quality events that do not escalate properly are among the most common 483 findings. Your QMS should have automated escalation rules so that no CAPA, deviation, or complaint quietly ages without supervisory visibility.

Conclusion

The DOGE environment at FDA has produced a paradox: fewer resources, sharper enforcement. Warning letters are up. Untitled letters are up. AI-driven inspection targeting is now operational. Unannounced overseas inspections are expanding.

What has changed is that inspections are now more likely to hit companies that data identifies as high-risk — and less likely to be evenly distributed across an industry through routine scheduling. That is not a lower inspection burden for most companies. For companies with open quality system gaps, it is a higher one.

The quality leaders who understand this are not waiting for inspection frequency to recover. They are operating as if an inspector with full data access could arrive at any time — because under Elsa, the agency now has a model that behaves that way.

If your QMS is not inspection-ready today, the time to fix it is before the data flags you.

Request a demo of Cloudtheapp to see how regulated companies maintain inspection-ready quality systems, regardless of how frequently FDA shows up at the door.

This post created by and appeared first on Cloudtheapp